France· FR:64426906
HARVONI 90 mg/400 mg, comprimé pelliculé
A medicinal product containing lédipasvir + sofosbuvir, registered in France by GILEAD SCIENCES IRELAND UC (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LÉDIPASVIR + SOFOSBUVIR
- Manufacturer
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300008851 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 28 comprimé(s)EUR 11.16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lédipasvir + sofosbuvir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesHarvoniGilead Sciences, Inc
- CzechiaHARVONIGilead Sciences Ireland UC, Carrigtohill
- United KingdomHarvoni 33.75mg/150mg granules sachetsGilead Sciences Ltd
- IrelandHarvoni 33.75 mg/150 mg Coated granulesGilead Sciences Ireland UC
- IcelandHarvoniGilead Sciences Ireland UC*
- FinlandHarvoniGilead Sciences Ireland UC
- NetherlandsHarvoni 33,75 mg/150 mg, granulaatGilead Sciences Ireland UC
- PolandHarvoniGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Harvoni
- Liechtenstein · Harvoni
- Norway · Harvoni
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd9ac17e-7510-4702-a7c9-afb94eadf740 GET /v1/drugs/bd9ac17e-7510-4702-a7c9-afb94eadf740?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64426906",
"date_amm": "2014-11-17",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/958",
"substance": "LÉDIPASVIR + SOFOSBUVIR",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about lédipasvir + sofosbuvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.